Affinity Biopharma is a global, clinical stage biopharmaceutical company focused on advancing innovative technology and first-in-class anti-tumor treatment. We have established Tumor MicroEnvironment Activated (TMEA) platform technology including TMEA-SMDC, TMEAbody®, TMEAkine® and TMEA-ICE® platforms, which allow selective unleash of the drug in the tumor microenvironment, reducing “On target, off tumor toxicity” and dramatically improving the therapeutic index. Affinity’s proprietary TMEA platform® could be broadly applied to therapeutic small molecules, cytokines, antibodies, fusion proteins, and ADC.
Company Details
- Founded
- -
- Address
- Shanghai, Cn
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.affinity.net.cn/
- HQ
- Shanghai
Affinity Biopharmaceutical Questions
Affinity Biopharmaceutical's website is http://www.affinity.net.cn/
Affinity Biopharmaceutical's LinkedIn profile is https://cn.linkedin.com/company/affinity-biopharma
Affinity Biopharmaceutical's industry is
Biotechnology Research
Affinity Biopharmaceutical's top competitors are
Idience,
3h Health Investment,
Chengdu Kanghong Pharmaceutical Group Co.,ltd.,
Sichuan Venture Capital,
Axter Therapeutics Co. Ltd,
Redhill Capital 丹麓资本,
Sutro Biopharma, Inc.,
Hangzhou Dac Biotech Co., Ltd.,
Mitoimmune Therapeutics Inc.,
Yield Capital Llc.
Affinity Biopharmaceutical's categories are Biotechnology Research
Affinity Biopharmaceutical's founding year is 2013
